Efficacy and safety of sublingual immunotherapy (Q35849524)

10 August 2017

1 reference

title

Efficacy and safety of sublingual immunotherapy (English)

1 reference

10 August 2017

1 reference

1

Giovanni Passalacqua

1 reference

10 August 2017

Giorgio Walter Canonica

series ordinal

5

object named as

Giorgio Walter Canonica

1 reference

10 August 2017

Laura Guerra

2

1 reference

10 August 2017

Mercedes Pasquali

series ordinal

3

1 reference

10 August 2017

Carlo Lombardi

series ordinal

4

1 reference

10 August 2017

publication date

1 July 2004

1 reference

Annals of Allergy, Asthma & Immunology

10 August 2017

published in

1 reference

10 August 2017

volume

93

1 reference

10 August 2017

issue

1

1 reference

10 August 2017

page(s)

3-12; quiz 12-3, 103

1 reference

PROPHYLACTIC INOCULATION AGAINST HAY FEVER

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Bronchial hypersensitization and hyposensitization in man

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Local nasal desensitization in allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Orally Administered Grass Pollen

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Fatalities from immunotherapy (IT) and skin testing (ST)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Survey of fatalities from skin testing and immunotherapy 1985-1989.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

1 reference

7 January 2021

Allergic rhinitis and its impact on asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Immunomodulation during sublingual therapy in allergic children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Clinical guidelines: developing guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Long-lasting clinical efficacy of allergen specific immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

A prospective study on the safety of immunotherapy in children with severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Immunotherapy as an effective tool in allergy treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Systemic reactions from allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Safety of sublingual-swallow immunotherapy in children and adults

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

1 reference

7 January 2021

Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Severe anaphylaxis to kiwi fruit: Immunologic changes related to successful sublingual allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Specific immunotherapy prevents increased levels of allergen-specific IL-4- and IL-13-producing cells during pollen season

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Mechanisms of allergen-specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Decrease of allergen-specific T-cell response induced by local nasal immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Sublingual swallow or spit?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Determinants of patient compliance with allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Noninjection routes for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Oral and sublingual immunotherapy in paediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Advances in upper airway diseases and allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Sublingual immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

Specific allergen immunotherapy: time for alternatives?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961440-8

7 January 2021

10.1016/S1081-1206(10)61440-8

Identifiers

DOI

1 reference

10 August 2017

1 reference